Most humans have pre-existing immunity to influenza viruses. In this study, volunteers (ages
of 18–85 years) were vaccinated with split, inactivated Fluzone ™ influenza vaccine in four …

The development of a safe and effective vaccine is a key requirement to overcoming the
COVID-19 pandemic. Recombinant proteins represent the most reliable and safe vaccine …

Most preclinical animal studies test influenza vaccines in immunologically naive animal
models, even though the results of vaccination may not accurately reflect the effectiveness of …

Influenza virus poses an ongoing human health threat with pandemic potential. Due to
mutations in circulating strains, formulating effective vaccines remains a challenge. The use of …

A key to improving vaccine design and vaccination strategy is to understand the mechanism
behind the variation of vaccine response with host factors. Glycosylation, a critical modulator …

Pre-existing immunity to influenza is dependent on a number of factors and can vary greatly
within and across influenza subtypes. In this study, volunteers (aged 18–85 years) were …

Influenza is a global health concern with millions of infections occurring yearly. Seasonal flu
vaccines are one way to combat this virus; however, they are poorly protective against …

The seasonal influenza vaccine is only effective in half of the vaccinated population. To identify
determinants of vaccine efficacy, we used data from > 1,300 vaccination events to predict …

Influenza B viruses (IBV) can cause severe disease and death much like influenza A viruses
(IAV), with a disproportionate number of infections in children. Despite moving to a …

Current seasonal influenza vaccines are limited in that they need to be reformulated every
year in order to account for the constant mutation of the virus. Hemagglutinin (HA) …